ARUKA BIO, INC.

PRINCETON, NJ · Founded 2023 · CIK 0001991781 · Biotech · Private

Targeted cancer therapies using engineered biology

arukabio.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$3.6M
2 Form D · Apr 2024
29 months since last filing
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$4,000
Private capital raisedForm D · SEC$3,550,000
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2317ProtoKinetix, Inc.—$3.8M
2318CERO THERAPEUTICS HOLDINGS, INC.—$16M
2319INMUNE BIO, INC.—$8.0M
2320ARUKA BIO, INC.—$3.6M
2321Genomics PLC——
2322Lennham Pharmaceuticals, Inc.—$3.5M
2323SUS CLINICALS INC—$3.5M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 3 related persons
  • NARESHKUMAR JAINDirector · Executive Officer
  • NARESHKUMAR JAIN, PH.D.Director · Executive Officer
  • SIDDHARTHA MUKHERJEEDirector · Executive Officer

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.